Myelosuppressive Agents

DrugDrug NameDrug Indication
DB00008Peginterferon alfa-2aPeginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].
DB00018Interferon alfa-n3For the intralesional treatment of refractory or recurring external condylomata acuminata.
DB00022Peginterferon alfa-2bPeginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
DB00041AldesleukinFor treatment of adults with metastatic renal cell carcinoma.
DB00056Gemtuzumab ozogamicinIndicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).
DB00069Interferon alfacon-1For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma
DB00073RituximabFor treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
DB00078Ibritumomab tiuxetanFor treatment of non-Hodgkin's lymphoma
DB00081TositumomabFor treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)
DB00087AlemtuzumabAlemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.
DB00112BevacizumabAs part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.
DB00120L-PhenylalanineL-phenylalanine may be helpful in some with depression. It may also be useful in the treatment of vitiligo. There is some evidence that L-phenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs.
DB00188BortezomibFor treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.
DB00242CladribineFor the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
DB00262CarmustineFor the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
DB00276AmsacrineFor treatment of acute myeloid leukaemia.
DB00291ChlorambucilFor treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
DB00293RaltitrexedFor the treatment of malignant neoplasm of colon and rectum
DB00305MitomycinFor treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery.
DB00307BexaroteneUsed orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
DB00309VindesineFor the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
DB00322FloxuridineFor palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Also for the palliative management of liver cancer (usually administered by hepatic intra-arterial infusion).
DB00352TioguanineFor remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
DB00361VinorelbineFor the treatment of non-small-cell lung carcinoma.
DB00380DexrazoxaneFor reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
DB00398SorafenibSorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
DB00428StreptozocinFor the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).
DB00441GemcitabineGemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; metastatic ovarian cancer; inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer; and locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.
DB00444TeniposideTeniposide is used for the treatment of refractory acute lymphoblastic leukaemia
DB00445EpirubicinFor use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
DB00446ChloramphenicolUsed in treatment of cholera, as it destroys the vibrios and decreases the diarrhea. It is effective against tetracycline-resistant vibrios. It is also used in eye drops or ointment to treat bacterial conjunctivitis.
DB00480LenalidomideLenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
DB00488AltretamineFor use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.
DB00495ZidovudineUsed in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
DB00515CisplatinFor the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
DB00526OxaliplatinUsed in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
DB00531CyclophosphamideCyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
DB00544FluorouracilFor the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
DB00550PropylthiouracilUsed to manage hyperthyroidism which is due to an overactive thyroid gland (Grave's disease).
DB00552PentostatinFor the treatment of hairy cell leukaemia refractory to alpha interferon.
DB00563MethotrexateMethotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe, active rheumatoid arthritis (ACR criteria), or children with active polyarticular-course juvenile rheumatoid arthritis.
DB00564CarbamazepineFor the treatment of epilepsy and pain associated with true trigeminal neuralgia.
DB00570VinblastineFor treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
DB00601LinezolidFor the treatment of bacterial infections caused by susceptible strains of vancomycin resistant Enterococcus faecium, Staphylococcal aureus (methicillin resistant and susceptible strains), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae.
DB00619ImatinibFor the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
DB00631ClofarabineFor the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
DB00642PemetrexedUsed in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
DB00694DaunorubicinFor remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
DB00762IrinotecanFor the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
DB00763MethimazoleFor the treatment of hyperthyroidism, goiter, Graves disease and psoriasis.
DB00773EtoposideFor use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
DB00851DacarbazineFor the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
DB00853TemozolomideFor the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme. Also used as maintenance therapy for glioblastoma multiforme.
DB00864TacrolimusFor use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
DB00877SirolimusFor the prophylaxis of organ rejection in patients receiving renal transplants.
DB00888MechlorethamineFor the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.
DB00928AzacitidineFor treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
DB00958CarboplatinFor the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide. It is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
DB00970DactinomycinFor the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen
DB00987CytarabineFor the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
DB00997DoxorubicinDoxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
DB01005HydroxyureaFor management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
DB01008BusulfanFor use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
DB01030TopotecanFor the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy.
DB01033MercaptopurineFor remission induction and maintenance therapy of acute lymphatic leukemia.
DB01041ThalidomideFor the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
DB01042MelphalanFor the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.
DB01073FludarabineFor the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
DB01099FlucytosineFor the treatment (in combination with amphotericin B) of serious infections caused by susceptible strains of Candida (septicemia, endocarditis and urinary system infections) and/or Cryptococcus (meningitis and pulmonary infections).
DB01101CapecitabineFor the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
DB01168ProcarbazineFor use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.
DB01169Arsenic trioxideFor induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
DB01177IdarubicinFor the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
DB01181IfosfamideUsed as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
DB01204MitoxantroneFor the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
DB01206LomustineFor the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
DB01229PaclitaxelUsed in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
DB01248DocetaxelFor the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
DB01254DasatinibFor the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
DB01262DecitabineFor treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups (scores ≥0.5).
DB01280NelarabineFor the treatment of pediatric and adult patients with acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
DB01590EverolimusEverolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
DB02546VorinostatFor the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.
DB04572ThiotepaThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
DB04845IxabepiloneInvestigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified).
DB04868NilotinibFor the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
DB05015BelinostatBelinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia [A19161].
DB05109TrabectedinIndicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in Europe, Russia and South Korea. Approved for orphan drug status by the U.S. FDA for treatment of soft tissue sarcomas and ovarian cancer. Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, ovarian cancer, pediatric indications, sarcoma, and solid tumors.
DB05773Trastuzumab emtansineUsed in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
DB06287TemsirolimusFor the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
DB06616BosutinibTreatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.
DB06769BendamustineBendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
DB06772CabazitaxelFor treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
DB08871EribulinFor the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
DB08877RuxolitinibTreatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).
DB08889CarfilzomibCarfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate.
DB08895TofacitinibFor the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.
DB08901PonatinibPonatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
DB08910PomalidomidePomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
DB08935ObinutuzumabObinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
DB09042Tedizolid PhosphateTedizolid Phosphate is an oxazolidinone antibacterial drug indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.
DB09052BlinatumomabIndicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
DB09053IbrutinibIbrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia. Ibrutinib is also indicated for the treatment of patients with Waldenström's Macroglobulinemia (WM). In August 2017, ibrutinib was approved for the treatment of chronic graft versus host disease patients who have failed one or more other therapies [L937].
DB09073PalbociclibPalbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
DB09074OlaparibOlaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
DB09077DinutuximabDinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.
DrugDrug NameTargetType
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 2target
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 1target
DB00008Peginterferon alfa-2aCytochrome P450 1A2enzyme
DB00018Interferon alfa-n3Interferon alpha/beta receptor 1target
DB00018Interferon alfa-n3Interferon alpha/beta receptor 2target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 1target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 2target
DB00022Peginterferon alfa-2bCytochrome P450 1A2enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2D6enzyme
DB00041AldesleukinInterleukin-2 receptor subunit betatarget
DB00041AldesleukinInterleukin-2 receptor subunit alphatarget
DB00041AldesleukinCytokine receptor common subunit gammatarget
DB00041AldesleukinProstaglandin G/H synthase 2enzyme
DB00041AldesleukinCytosolic phospholipase A2enzyme
DB00041AldesleukinCytochrome P450 3A4enzyme
DB00041AldesleukinXanthine dehydrogenase/oxidaseenzyme
DB00041AldesleukinCytochrome P450 2E1enzyme
DB00056Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00056Gemtuzumab ozogamicinComplement C1r subcomponenttarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Atarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Btarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Ctarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00056Gemtuzumab ozogamicinComplement C1s subcomponenttarget
DB00056Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00069Interferon alfacon-1Interferon alpha/beta receptor 1target
DB00069Interferon alfacon-1Interferon alpha/beta receptor 2target
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00073RituximabComplement C1r subcomponenttarget
DB00073RituximabComplement C1q subcomponent subunit Atarget
DB00073RituximabComplement C1q subcomponent subunit Btarget
DB00073RituximabComplement C1q subcomponent subunit Ctarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00073RituximabComplement C1s subcomponenttarget
DB00073RituximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00073RituximabB-lymphocyte antigen CD20target
DB00078Ibritumomab tiuxetanB-lymphocyte antigen CD20target
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00078Ibritumomab tiuxetanComplement C1r subcomponenttarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Atarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Btarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Ctarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00078Ibritumomab tiuxetanComplement C1s subcomponenttarget
DB00078Ibritumomab tiuxetanHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00081TositumomabB-lymphocyte antigen CD20target
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00081TositumomabComplement C1r subcomponenttarget
DB00081TositumomabComplement C1q subcomponent subunit Atarget
DB00081TositumomabComplement C1q subcomponent subunit Btarget
DB00081TositumomabComplement C1q subcomponent subunit Ctarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00081TositumomabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00087AlemtuzumabCAMPATH-1 antigentarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00087AlemtuzumabComplement C1r subcomponenttarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Atarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Btarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Ctarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00087AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB00120L-PhenylalanineTyrosine aminotransferasetarget
DB00120L-PhenylalanineLarge neutral amino acids transporter small subunit 2target
DB00120L-PhenylalaninePhenylalanine--tRNA ligase alpha subunittarget
DB00120L-PhenylalaninePhenylalanine-4-hydroxylasetarget
DB00120L-PhenylalaninePhenylalanine--tRNA ligase, mitochondrialtarget
DB00120L-PhenylalaninePhenylalanine--tRNA ligase beta subunittarget
DB00120L-PhenylalanineTyrosine 3-monooxygenasetarget
DB00120L-PhenylalanineMonocarboxylate transporter 10transporter
DB00188BortezomibCytochrome P450 3A4enzyme
DB00188BortezomibCytochrome P450 2C19enzyme
DB00188BortezomibCytochrome P450 1A2enzyme
DB00188BortezomibCytochrome P450 2D6enzyme
DB00188BortezomibCytochrome P450 2C9enzyme
DB00188BortezomibProteasome subunit beta type-5target
DB00188BortezomibProteasome subunit beta type-1target
DB00242CladribinePurine nucleoside phosphorylasetarget
DB00242CladribineDNAtarget
DB00242CladribineDeoxycytidine kinaseenzyme
DB00242CladribineRibonucleoside-diphosphate reductase large subunittarget
DB00242CladribineRibonucleoside-diphosphate reductase subunit M2target
DB00242CladribineRibonucleoside-diphosphate reductase subunit M2 Btarget
DB00242CladribineDNA polymerase alpha catalytic subunittarget
DB00242CladribineDNA polymerase epsilon catalytic subunit Atarget
DB00242CladribineDNA polymerase epsilon subunit 2target
DB00242CladribineDNA polymerase epsilon subunit 3target
DB00242CladribineDNA polymerase epsilon subunit 4target
DB00242CladribineSolute carrier family 22 member 2transporter
DB00242CladribineSolute carrier family 22 member 1transporter
DB00242CladribineATP-binding cassette sub-family G member 2transporter
DB00242CladribineSolute carrier family 28 member 3transporter
DB00262CarmustineGlutathione reductase, mitochondrialtarget
DB00262CarmustineDNAtarget
DB00262CarmustineCytochrome P450 1A2enzyme
DB00262CarmustineRNAtarget
DB00276AmsacrineDNA topoisomerase 2-alphatarget
DB00276AmsacrineDNAtarget
DB00276AmsacrinePotassium voltage-gated channel subfamily H member 2target
DB00276AmsacrineMultidrug resistance protein 1transporter
DB00276AmsacrineCytochrome P450 2D6enzyme
DB00276AmsacrineAlpha-1-acid glycoprotein 1target
DB00276AmsacrineSerum albumintarget
DB00291ChlorambucilDNAtarget
DB00291ChlorambucilGlutathione S-transferase Penzyme
DB00291ChlorambucilSolute carrier organic anion transporter family member 1A2transporter
DB00293RaltitrexedThymidylate synthasetarget
DB00293RaltitrexedFolylpolyglutamate synthase, mitochondrialtarget
DB00305MitomycinDNAtarget
DB00305MitomycinNADPH--cytochrome P450 reductaseenzyme
DB00305MitomycinMultidrug resistance protein 1transporter
DB00307BexaroteneRetinoic acid receptor RXR-betatarget
DB00307BexaroteneCytochrome P450 3A4enzyme
DB00307BexaroteneRetinoic acid receptor RXR-alphatarget
DB00307BexaroteneRetinoic acid receptor RXR-gammatarget
DB00307BexaroteneCytochrome P450 2C9enzyme
DB00309VindesineTubulin beta-1 chaintarget
DB00309VindesineCytochrome P450 3A4enzyme
DB00322FloxuridineThymidylate synthasetarget
DB00322FloxuridineThymidine phosphorylaseenzyme
DB00322FloxuridineCytochrome P450 2C9enzyme
DB00352TioguanineDNAtarget
DB00352TioguanineMultidrug resistance-associated protein 4transporter
DB00352TioguanineHypoxanthine-guanine phosphoribosyltransferaseenzyme
DB00361VinorelbineTubulin beta chaintarget
DB00361VinorelbineCytochrome P450 3A4enzyme
DB00361VinorelbineMultidrug resistance protein 1transporter
DB00361VinorelbineCytochrome P450 2D6enzyme
DB00380DexrazoxaneDNA topoisomerase 2-alphatarget
DB00380DexrazoxaneDNA topoisomerase 2-betatarget
DB00398SorafenibSerine/threonine-protein kinase B-raftarget
DB00398SorafenibReceptor-type tyrosine-protein kinase FLT3target
DB00398SorafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DB00398SorafenibVascular endothelial growth factor receptor 3target
DB00398SorafenibPlatelet-derived growth factor receptor betatarget
DB00398SorafenibMast/stem cell growth factor receptor Kittarget
DB00398SorafenibVascular endothelial growth factor receptor 2target
DB00398SorafenibCytochrome P450 3A4enzyme
DB00398SorafenibUDP-glucuronosyltransferase 1-9enzyme
DB00398SorafenibCytochrome P450 2B6enzyme
DB00398SorafenibCytochrome P450 2C8enzyme
DB00398SorafenibCytochrome P450 3A5enzyme
DB00398SorafenibCytochrome P450 3A7enzyme
DB00398SorafenibCytochrome P450 2C9enzyme
DB00398SorafenibMultidrug resistance-associated protein 4transporter
DB00398SorafenibMultidrug resistance protein 1transporter
DB00398SorafenibCanalicular multispecific organic anion transporter 1transporter
DB00398SorafenibATP-binding cassette sub-family G member 2transporter
DB00398SorafenibCytochrome P450 1A2enzyme
DB00398SorafenibCytochrome P450 2C19enzyme
DB00398SorafenibCytochrome P450 2D6enzyme
DB00398SorafenibUDP-glucuronosyltransferase 1-1enzyme
DB00398SorafenibRalA-binding protein 1transporter
DB00398SorafenibFibroblast growth factor receptor 1target
DB00398SorafenibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB00398SorafenibVascular endothelial growth factor receptor 1target
DB00428StreptozocinDNAtarget
DB00428StreptozocinMultidrug resistance protein 1transporter
DB00428StreptozocinSolute carrier family 2, facilitated glucose transporter member 2target
DB00428StreptozocinO-GlcNAcase BT_4395target
DB00428StreptozocinCytochrome P450 1A1enzyme
DB00428StreptozocinCytochrome P450 1A2enzyme
DB00428StreptozocinCytochrome P450 2E1enzyme
DB00428StreptozocinBifunctional protein NCOATtarget
DB00441GemcitabineRibonucleoside-diphosphate reductase large subunittarget
DB00441GemcitabineUMP-CMP kinasetarget
DB00441GemcitabineThymidylate synthasetarget
DB00441GemcitabineCytidine deaminaseenzyme
DB00441GemcitabineDeoxycytidine kinaseenzyme
DB00441GemcitabineMultidrug resistance protein 1transporter
DB00441GemcitabineMultidrug resistance-associated protein 7transporter
DB00441GemcitabineEquilibrative nucleoside transporter 1transporter
DB00441GemcitabineDNAtarget
DB00441GemcitabineSodium/nucleoside cotransporter 1transporter
DB00441GemcitabineEquilibrative nucleoside transporter 2transporter
DB00441GemcitabineSolute carrier family 28 member 3transporter
DB00444TeniposideDNA topoisomerase 2-alphatarget
DB00444TeniposideCytochrome P450 2C19enzyme
DB00444TeniposideCytochrome P450 2C9enzyme
DB00444TeniposideCytochrome P450 3A4enzyme
DB00444TeniposideMultidrug resistance-associated protein 6transporter
DB00444TeniposideATP-binding cassette sub-family G member 2transporter
DB00444TeniposideCytochrome P450 3A5enzyme
DB00445EpirubicinChromodomain-helicase-DNA-binding protein 1target
DB00445EpirubicinDNA topoisomerase 2-alphatarget
DB00445EpirubicinDNAtarget
DB00445EpirubicinMultidrug resistance-associated protein 1transporter
DB00445EpirubicinUDP-glucuronosyltransferase 2B7enzyme
DB00445EpirubicinCytosolic phospholipase A2enzyme
DB00446ChloramphenicolComplement decay-accelerating factortarget
DB00446ChloramphenicolDr hemagglutinin structural subunittarget
DB00446ChloramphenicolCytochrome P450 2C19enzyme
DB00446ChloramphenicolCytochrome P450 3A4enzyme
DB00446ChloramphenicolCytochrome P450 3A5enzyme
DB00446ChloramphenicolCytochrome P450 3A7enzyme
DB00446ChloramphenicolSolute carrier family 22 member 6transporter
DB00446Chloramphenicol50S ribosomal protein L16target
DB00446ChloramphenicolChloramphenicol acetyltransferase 3enzyme
DB00446ChloramphenicolChloramphenicol acetyltransferaseenzyme
DB00446ChloramphenicolChloramphenicol 3-O phosphotransferaseenzyme
DB00446ChloramphenicolCytochrome P450 2C8enzyme
DB00446ChloramphenicolCytochrome P450 2C9enzyme
DB00480LenalidomideProstaglandin G/H synthase 2target
DB00480LenalidomideTumor necrosis factor ligand superfamily member 11target
DB00480LenalidomideCadherin-5target
DB00480LenalidomideProtein cereblontarget
DB00480LenalidomideMultidrug resistance protein 1transporter
DB00488AltretamineDNAtarget
DB00495ZidovudineSerum albumincarrier
DB00495ZidovudineCytochrome P450 2A6enzyme
DB00495ZidovudineCytochrome P450 2C19enzyme
DB00495ZidovudineCytochrome P450 2C8enzyme
DB00495ZidovudineCytochrome P450 2C9enzyme
DB00495ZidovudineCytochrome P450 3A4enzyme
DB00495ZidovudineReverse transcriptase/RNaseHtarget
DB00495ZidovudineSolute carrier family 22 member 2transporter
DB00495ZidovudineSolute carrier family 22 member 6transporter
DB00495ZidovudineSolute carrier family 22 member 7transporter
DB00495ZidovudineSolute carrier family 22 member 8transporter
DB00495ZidovudineSolute carrier family 22 member 11transporter
DB00495ZidovudineSodium/nucleoside cotransporter 1transporter
DB00495ZidovudineEquilibrative nucleoside transporter 2transporter
DB00495ZidovudineMultidrug resistance protein 1transporter
DB00495ZidovudineMultidrug resistance-associated protein 4transporter
DB00495ZidovudineMultidrug resistance-associated protein 5transporter
DB00495ZidovudineATP-binding cassette sub-family G member 2transporter
DB00495ZidovudineTelomerase reverse transcriptasetarget
DB00495ZidovudineThymidine kinase, cytosolicenzyme
DB00495ZidovudineUDP-glucuronosyltransferase 2B7enzyme
DB00515CisplatinDNAtarget
DB00515CisplatinCanalicular multispecific organic anion transporter 2transporter
DB00515CisplatinMultidrug resistance-associated protein 5transporter
DB00515CisplatinCanalicular multispecific organic anion transporter 1transporter
DB00515CisplatinSolute carrier family 22 member 2transporter
DB00515CisplatinHigh affinity copper uptake protein 1transporter
DB00515CisplatinProbable low affinity copper uptake protein 2transporter
DB00515CisplatinMultidrug resistance-associated protein 6transporter
DB00515CisplatinMultidrug resistance protein 1transporter
DB00515CisplatinCopper-transporting ATPase 2transporter
DB00515CisplatinCopper-transporting ATPase 1transporter
DB00515CisplatinProstaglandin G/H synthase 2enzyme
DB00515CisplatinMyeloperoxidaseenzyme
DB00515CisplatinXanthine dehydrogenase/oxidaseenzyme
DB00515CisplatinArylamine N-acetyltransferaseenzyme
DB00515CisplatinCytochrome P450 2C9enzyme
DB00515CisplatinCytochrome P450 2B6enzyme
DB00515CisplatinCholinesteraseenzyme
DB00515CisplatinCytochrome P450 4A11enzyme
DB00515CisplatinATP-binding cassette sub-family G member 2transporter
DB00515CisplatinGlutathione S-transferase theta-1enzyme
DB00515CisplatinMetallothionein-1Aenzyme
DB00515CisplatinMetallothionein-2enzyme
DB00515CisplatinSuperoxide dismutase [Cu-Zn]enzyme
DB00515CisplatinGlutathione S-transferase Penzyme
DB00515CisplatinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00515CisplatinGlutathione S-transferase Mu 1enzyme
DB00515CisplatinDNA-3-methyladenine glycosylasetarget
DB00515CisplatinAlpha-2-macroglobulintarget
DB00515CisplatinSerum albumincarrier
DB00515CisplatinSerotransferrintarget
DB00515CisplatinCopper transport protein ATOX1target
DB00526OxaliplatinDNAtarget
DB00526OxaliplatinSolute carrier family 22 member 2transporter
DB00526OxaliplatinSolute carrier family 22 member 1transporter
DB00526OxaliplatinHigh affinity copper uptake protein 1transporter
DB00526OxaliplatinSolute carrier family 22 member 3transporter
DB00526OxaliplatinATP-binding cassette sub-family G member 2transporter
DB00526OxaliplatinCytochrome P450 1A1enzyme
DB00526OxaliplatinCytochrome P450 1A2enzyme
DB00526OxaliplatinCytochrome P450 1B1enzyme
DB00526OxaliplatinCytochrome P450 2E1enzyme
DB00526OxaliplatinGlutathione S-transferase theta-1enzyme
DB00526OxaliplatinMetallothionein-1Aenzyme
DB00526OxaliplatinMetallothionein-2enzyme
DB00526OxaliplatinMyeloperoxidaseenzyme
DB00526OxaliplatinSuperoxide dismutase [Cu-Zn]enzyme
DB00526OxaliplatinGlutathione S-transferase Penzyme
DB00526OxaliplatinGlutathione S-transferase Mu 1enzyme
DB00526OxaliplatinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00526OxaliplatinCanalicular multispecific organic anion transporter 1transporter
DB00526OxaliplatinCopper-transporting ATPase 2transporter
DB00526OxaliplatinCopper-transporting ATPase 1transporter
DB00531CyclophosphamideDNAtarget
DB00531CyclophosphamideCytochrome P450 2B6enzyme
DB00531CyclophosphamideCytochrome P450 2C9enzyme
DB00531CyclophosphamideCytochrome P450 3A4enzyme
DB00531CyclophosphamideCytochrome P450 2C19enzyme
DB00531CyclophosphamideMultidrug resistance protein 1transporter
DB00531CyclophosphamideCytochrome P450 2A6enzyme
DB00531CyclophosphamideCytochrome P450 2C18enzyme
DB00531CyclophosphamideCytochrome P450 2C8enzyme
DB00531CyclophosphamideCytochrome P450 2D6enzyme
DB00531CyclophosphamideCytochrome P450 3A7enzyme
DB00531CyclophosphamideCytochrome P450 3A5enzyme
DB00531CyclophosphamideNuclear receptor subfamily 1 group I member 2target
DB00544FluorouracilThymidylate synthasetarget
DB00544FluorouracilCytochrome P450 1A2enzyme
DB00544FluorouracilThymidine phosphorylaseenzyme
DB00544FluorouracilSerum albumincarrier
DB00544FluorouracilCytochrome P450 2C9enzyme
DB00544FluorouracilDihydropyrimidine dehydrogenase [NADP(+)]enzyme
DB00544FluorouracilUridine phosphorylase 1enzyme
DB00544FluorouracilUridine phosphorylase 2enzyme
DB00544FluorouracilDNAtarget
DB00544FluorouracilRNAtarget
DB00544FluorouracilCytochrome P450 2A6enzyme
DB00544FluorouracilCytochrome P450 2C8enzyme
DB00544FluorouracilMethylenetetrahydrofolate reductaseenzyme
DB00544FluorouracilThymidylate synthaseenzyme
DB00544FluorouracilUridine 5'-monophosphate synthaseenzyme
DB00544FluorouracilAmidophosphoribosyltransferaseenzyme
DB00544FluorouracilSolute carrier family 22 member 7transporter
DB00544FluorouracilEquilibrative nucleoside transporter 1transporter
DB00544FluorouracilATP-binding cassette sub-family G member 2transporter
DB00544FluorouracilCanalicular multispecific organic anion transporter 2transporter
DB00544FluorouracilMultidrug resistance-associated protein 4transporter
DB00544FluorouracilMultidrug resistance-associated protein 5transporter
DB00550PropylthiouracilThyroid peroxidasetarget
DB00550PropylthiouracilMyeloperoxidaseenzyme
DB00550PropylthiouracilDopamine beta-hydroxylaseenzyme
DB00552PentostatinAdenosine deaminasetarget
DB00563MethotrexateDihydrofolate reductasetarget
DB00563MethotrexateAldehyde oxidaseenzyme
DB00563MethotrexateMethylenetetrahydrofolate reductaseenzyme
DB00563MethotrexateSerum albumincarrier
DB00563MethotrexateCanalicular multispecific organic anion transporter 2transporter
DB00563MethotrexateMultidrug resistance-associated protein 4transporter
DB00563MethotrexateMultidrug resistance-associated protein 1transporter
DB00563MethotrexateSolute carrier family 22 member 6transporter
DB00563MethotrexateMultidrug resistance-associated protein 7transporter
DB00563MethotrexateSolute carrier family 22 member 8transporter
DB00563MethotrexateCanalicular multispecific organic anion transporter 1transporter
DB00563MethotrexateMultidrug resistance protein 1transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1A2transporter
DB00563MethotrexateMonocarboxylate transporter 1transporter
DB00563MethotrexateATP-binding cassette sub-family C member 11transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1B3transporter
DB00563MethotrexateSolute carrier family 22 member 11transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1C1transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 3A1transporter
DB00563MethotrexateATP-binding cassette sub-family G member 2transporter
DB00563MethotrexateSolute carrier family 22 member 7transporter
DB00563MethotrexateSolute carrier organic anion transporter family member 1B1transporter
DB00563Methotrexate6-phosphogluconate dehydrogenase, decarboxylatingenzyme
DB00563MethotrexateProton-coupled folate transportertransporter
DB00563MethotrexateFolylpolyglutamate synthase, mitochondrialenzyme
DB00563MethotrexateGamma-glutamyl hydrolaseenzyme
DB00563MethotrexateDihydrofolate reductaseenzyme
DB00563MethotrexateThymidylate synthaseenzyme
DB00563MethotrexateBifunctional purine biosynthesis protein PURHenzyme
DB00563MethotrexateSolute carrier organic anion transporter family member 4C1transporter
DB00563MethotrexateFolate transporter 1transporter
DB00563MethotrexateFolate receptor alphatransporter
DB00564CarbamazepineSodium channel protein type 5 subunit alphatarget
DB00564CarbamazepineCytochrome P450 2C8enzyme
DB00564CarbamazepineCytochrome P450 2B6enzyme
DB00564CarbamazepineCytochrome P450 3A4enzyme
DB00564CarbamazepineCytochrome P450 1A2enzyme
DB00564CarbamazepineCytochrome P450 2C19enzyme
DB00564CarbamazepineCytochrome P450 2C9enzyme
DB00564CarbamazepineMultidrug resistance protein 1transporter
DB00564CarbamazepineCytochrome P450 3A5enzyme
DB00564CarbamazepineCytochrome P450 3A7enzyme
DB00564CarbamazepineUDP-glucuronosyltransferase 2B7enzyme
DB00564CarbamazepineRalA-binding protein 1transporter
DB00564CarbamazepineCanalicular multispecific organic anion transporter 1transporter
DB00564CarbamazepineNeuronal acetylcholine receptor subunit alpha-4target
DB00564CarbamazepineNeuronal acetylcholine receptor subunit beta-2target
DB00564CarbamazepineNuclear receptor subfamily 1 group I member 2target
DB00570VinblastineTubulin beta chaintarget
DB00570VinblastineTranscription factor AP-1target
DB00570VinblastineCytochrome P450 3A4enzyme
DB00570VinblastineMultidrug resistance protein 1transporter
DB00570VinblastineMultidrug resistance-associated protein 1transporter
DB00570VinblastineCanalicular multispecific organic anion transporter 1transporter
DB00570VinblastineMultidrug resistance-associated protein 6transporter
DB00570VinblastineBile salt export pumptransporter
DB00570VinblastineSolute carrier family 22 member 2transporter
DB00570VinblastineTubulin alpha-1A chaintarget
DB00570VinblastineTubulin delta chaintarget
DB00570VinblastineTubulin epsilon chaintarget
DB00570VinblastineTubulin gamma-1 chaintarget
DB00570VinblastineCytochrome P450 2D6enzyme
DB00601Linezolid23S rRNAtarget
DB00601LinezolidAmine oxidase [flavin-containing] Aenzyme
DB00601LinezolidAmine oxidase [flavin-containing] Benzyme
DB00619ImatinibPlatelet-derived growth factor receptor betatarget
DB00619ImatinibTyrosine-protein kinase ABL1target
DB00619ImatinibMast/stem cell growth factor receptor Kittarget
DB00619ImatinibRET proto-oncogenetarget
DB00619ImatinibHigh affinity nerve growth factor receptortarget
DB00619ImatinibMacrophage colony-stimulating factor 1 receptortarget
DB00619ImatinibPlatelet-derived growth factor receptor alphatarget
DB00619ImatinibEpithelial discoidin domain-containing receptor 1target
DB00619ImatinibCytochrome P450 3A4enzyme
DB00619ImatinibBCR/ABL fusion protein isoform X9target
DB00619ImatinibCytochrome P450 1A2enzyme
DB00619ImatinibCytochrome P450 2D6enzyme
DB00619ImatinibCytochrome P450 2C9enzyme
DB00619ImatinibCytochrome P450 2C19enzyme
DB00619ImatinibCytochrome P450 3A5enzyme
DB00619ImatinibCytochrome P450 3A7enzyme
DB00619ImatinibSolute carrier family 22 member 1transporter
DB00619ImatinibMultidrug resistance protein 1transporter
DB00619ImatinibSolute carrier family 22 member 2transporter
DB00619ImatinibATP-binding cassette sub-family G member 2transporter
DB00619ImatinibATP-binding cassette sub-family A member 3transporter
DB00619ImatinibProstaglandin G/H synthase 1enzyme
DB00619ImatinibSerum albumincarrier
DB00619ImatinibAlpha-1-acid glycoprotein 1carrier
DB00631ClofarabineDNA polymerase alpha catalytic subunittarget
DB00631ClofarabineRibonucleoside-diphosphate reductase large subunittarget
DB00631ClofarabineDeoxycytidine kinaseenzyme
DB00631ClofarabineDNAtarget
DB00631ClofarabineATP-binding cassette sub-family G member 2transporter
DB00642PemetrexedThymidylate synthasetarget
DB00642PemetrexedDihydrofolate reductasetarget
DB00642PemetrexedTrifunctional purine biosynthetic protein adenosine-3target
DB00642PemetrexedDeoxycytidine kinaseenzyme
DB00642PemetrexedBifunctional purine biosynthesis protein PURHtarget
DB00642PemetrexedEquilibrative nucleoside transporter 1enzyme
DB00694DaunorubicinDNAtarget
DB00694DaunorubicinXanthine dehydrogenase/oxidaseenzyme
DB00694DaunorubicinCytochrome P450 3A5enzyme
DB00694DaunorubicinNADPH--cytochrome P450 reductaseenzyme
DB00694DaunorubicinMultidrug resistance protein 1transporter
DB00694DaunorubicinMultidrug resistance-associated protein 1transporter
DB00694DaunorubicinCanalicular multispecific organic anion transporter 1transporter
DB00694DaunorubicinSolute carrier family 22 member 2transporter
DB00694DaunorubicinMultidrug resistance-associated protein 6transporter
DB00694DaunorubicinBile salt export pumptransporter
DB00694DaunorubicinMultidrug resistance-associated protein 7transporter
DB00694DaunorubicinATP-binding cassette sub-family G member 2transporter
DB00694DaunorubicinDNA topoisomerase 2-alphatarget
DB00694DaunorubicinDNA topoisomerase 2-betatarget
DB00694DaunorubicinCytochrome P450 1A1enzyme
DB00694DaunorubicinCytochrome P450 1A2enzyme
DB00694DaunorubicinCytochrome P450 1B1enzyme
DB00694DaunorubicinCytochrome P450 3A4enzyme
DB00762IrinotecanDNA topoisomerase I, mitochondrialtarget
DB00762IrinotecanDNA topoisomerase 1target
DB00762IrinotecanCytochrome P450 3A4enzyme
DB00762IrinotecanCytochrome P450 3A5enzyme
DB00762IrinotecanUDP-glucuronosyltransferase 1-1enzyme
DB00762IrinotecanUDP-glucuronosyltransferase 1-9enzyme
DB00762IrinotecanLiver carboxylesterase 1enzyme
DB00762IrinotecanCytochrome P450 3A7enzyme
DB00762IrinotecanCytochrome P450 2B6enzyme
DB00762IrinotecanSolute carrier family 22 member 3transporter
DB00762IrinotecanSolute carrier organic anion transporter family member 1B1transporter
DB00762IrinotecanMultidrug resistance-associated protein 1transporter
DB00762IrinotecanATP-binding cassette sub-family G member 2transporter
DB00762IrinotecanSerum albumincarrier
DB00762IrinotecanCocaine esteraseenzyme
DB00762IrinotecanCholinesteraseenzyme
DB00762IrinotecanMultidrug resistance protein 1transporter
DB00762IrinotecanCanalicular multispecific organic anion transporter 1transporter
DB00763MethimazoleThyroid peroxidasetarget
DB00763MethimazoleCytochrome P450 1A2enzyme
DB00763MethimazoleCytochrome P450 2A6enzyme
DB00763MethimazoleCytochrome P450 2B6enzyme
DB00763MethimazoleCytochrome P450 2C19enzyme
DB00763MethimazoleCytochrome P450 2C9enzyme
DB00763MethimazoleCytochrome P450 2D6enzyme
DB00763MethimazoleCytochrome P450 2E1enzyme
DB00763MethimazoleCytochrome P450 3A4enzyme
DB00773EtoposideDNA topoisomerase 2-alphatarget
DB00773EtoposideCytochrome P450 3A4enzyme
DB00773EtoposideCanalicular multispecific organic anion transporter 2transporter
DB00773EtoposideMultidrug resistance-associated protein 6transporter
DB00773EtoposideMultidrug resistance protein 1transporter
DB00773EtoposideMultidrug resistance-associated protein 1transporter
DB00773EtoposideMultidrug resistance-associated protein 7transporter
DB00773EtoposideCanalicular multispecific organic anion transporter 1transporter
DB00773EtoposideATP-binding cassette sub-family G member 2transporter
DB00773EtoposideCytochrome P450 1A2enzyme
DB00773EtoposideCytochrome P450 2C8enzyme
DB00773EtoposideCytochrome P450 2E1enzyme
DB00773EtoposideCytochrome P450 3A5enzyme
DB00773EtoposideUDP-glucuronosyltransferase 1-1enzyme
DB00773EtoposideDNA topoisomerase 2-betatarget
DB00773EtoposideGlutathione S-transferase theta-1enzyme
DB00773EtoposideGlutathione S-transferase Penzyme
DB00773EtoposideProstaglandin G/H synthase 2enzyme
DB00773EtoposideProstaglandin G/H synthase 1enzyme
DB00851DacarbazineDNA polymerase alpha subunit Btarget
DB00851DacarbazineCytochrome P450 1A1enzyme
DB00851DacarbazineCytochrome P450 1A2enzyme
DB00851DacarbazineCytochrome P450 2E1enzyme
DB00851Dacarbazine6-phosphogluconate dehydrogenase, decarboxylatingtarget
DB00851DacarbazineDNAtarget
DB00853TemozolomideDNAtarget
DB00853TemozolomideCytochrome P450 3A4enzyme
DB00864TacrolimusPeptidyl-prolyl cis-trans isomerase FKBP1Atarget
DB00864TacrolimusCytochrome P450 3A4enzyme
DB00864TacrolimusCytochrome P450 3A5enzyme
DB00864TacrolimusCytochrome P450 3A7enzyme
DB00864TacrolimusMultidrug resistance protein 1transporter
DB00864TacrolimusATP-binding cassette sub-family A member 5transporter
DB00864TacrolimusSerum albumincarrier
DB00864TacrolimusAlpha-1-acid glycoprotein 1carrier
DB00877SirolimusPeptidyl-prolyl cis-trans isomerase FKBP1Atarget
DB00877SirolimusCytochrome P450 3A4enzyme
DB00877SirolimusSerine/threonine-protein kinase mTORtarget
DB00877SirolimusFibroblast growth factor 2target
DB00877SirolimusCytochrome P450 3A5enzyme
DB00877SirolimusCytochrome P450 3A7enzyme
DB00877SirolimusMultidrug resistance protein 1transporter
DB00877SirolimusSolute carrier organic anion transporter family member 1B1transporter
DB00877SirolimusMultidrug and toxin extrusion protein 1transporter
DB00888MechlorethamineDNAtarget
DB00928AzacitidineDNA (cytosine-5)-methyltransferase 1target
DB00928AzacitidineCytidine deaminaseenzyme
DB00928AzacitidineDNAtarget
DB00928AzacitidineRNAtarget
DB00958CarboplatinDNAtarget
DB00958CarboplatinHigh affinity copper uptake protein 1transporter
DB00958CarboplatinProbable low affinity copper uptake protein 2transporter
DB00958CarboplatinXanthine dehydrogenase/oxidaseenzyme
DB00958CarboplatinMyeloperoxidaseenzyme
DB00958CarboplatinGlutathione S-transferase theta-1enzyme
DB00958CarboplatinMetallothionein-1Aenzyme
DB00958CarboplatinMetallothionein-2enzyme
DB00958CarboplatinSuperoxide dismutase [Cu-Zn]enzyme
DB00958CarboplatinGlutathione S-transferase Penzyme
DB00958CarboplatinGlutathione S-transferase Mu 1enzyme
DB00958CarboplatinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00958CarboplatinCopper-transporting ATPase 1transporter
DB00958CarboplatinCopper-transporting ATPase 2transporter
DB00958CarboplatinATP-binding cassette sub-family G member 2transporter
DB00958CarboplatinCanalicular multispecific organic anion transporter 1transporter
DB00970DactinomycinDNAtarget
DB00970DactinomycinSolute carrier family 22 member 5transporter
DB00970DactinomycinMultidrug resistance protein 1transporter
DB00970DactinomycinMultidrug resistance-associated protein 6transporter
DB00970DactinomycinMultidrug resistance-associated protein 1transporter
DB00970DactinomycinATP-binding cassette sub-family G member 2transporter
DB00970DactinomycinDNA topoisomerase 2target
DB00987CytarabineDNA polymerase betatarget
DB00987CytarabineCytidine deaminaseenzyme
DB00987CytarabineSolute carrier family 22 member 2transporter
DB00987CytarabineSolute carrier family 22 member 1transporter
DB00987CytarabineMultidrug resistance-associated protein 7transporter
DB00987CytarabineEquilibrative nucleoside transporter 1transporter
DB00987CytarabineDNAtarget
DB00987CytarabineCytochrome P450 3A4enzyme
DB00987CytarabineDeoxycytidine kinaseenzyme
DB00987Cytarabine5'-nucleotidaseenzyme
DB00987CytarabineDeoxycytidylate deaminaseenzyme
DB00997DoxorubicinDNA topoisomerase 2-alphatarget
DB00997DoxorubicinDNAtarget
DB00997DoxorubicinCytochrome P450 3A4enzyme
DB00997DoxorubicinCytochrome P450 2D6enzyme
DB00997DoxorubicinCytochrome P450 2B6enzyme
DB00997DoxorubicinMultidrug resistance protein 1transporter
DB00997DoxorubicinCanalicular multispecific organic anion transporter 2transporter
DB00997DoxorubicinMultidrug resistance-associated protein 6transporter
DB00997DoxorubicinMultidrug resistance-associated protein 1transporter
DB00997DoxorubicinMultidrug resistance-associated protein 7transporter
DB00997DoxorubicinATP-binding cassette sub-family G member 2transporter
DB00997DoxorubicinBile salt export pumptransporter
DB00997DoxorubicinSolute carrier family 22 member 16transporter
DB00997DoxorubicinATP-binding cassette sub-family B member 8, mitochondrialtransporter
DB00997DoxorubicinCytochrome P450 1B1enzyme
DB00997DoxorubicinCarbonyl reductase [NADPH] 1enzyme
DB00997DoxorubicinCarbonyl reductase [NADPH] 3enzyme
DB00997DoxorubicinAlcohol dehydrogenase [NADP(+)]enzyme
DB00997DoxorubicinAldo-keto reductase family 1 member C3enzyme
DB00997DoxorubicinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00997DoxorubicinXanthine dehydrogenase/oxidaseenzyme
DB00997DoxorubicinNitric oxide synthase, endothelialenzyme
DB00997DoxorubicinNitric oxide synthase, inducibleenzyme
DB00997DoxorubicinNitric oxide synthase, brainenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialenzyme
DB00997DoxorubicinNADPH--cytochrome P450 reductaseenzyme
DB00997DoxorubicinRalA-binding protein 1transporter
DB00997DoxorubicinCanalicular multispecific organic anion transporter 1transporter
DB00997DoxorubicinSerum albumincarrier
DB00997DoxorubicinNucleolar and coiled-body phosphoprotein 1target
DB01005HydroxyureaRibonucleoside-diphosphate reductase large subunittarget
DB01005HydroxyureaCytochrome P450 2D6enzyme
DB01008BusulfanDNAtarget
DB01008BusulfanCytochrome P450 3A4enzyme
DB01008BusulfanGlutathione S-transferase A2enzyme
DB01008BusulfanGlutathione S-transferase A1enzyme
DB01008BusulfanGlutathione S-transferase Mu 1enzyme
DB01008BusulfanGlutathione S-transferase Penzyme
DB01008BusulfanMicrosomal glutathione S-transferase 2enzyme
DB01030TopotecanDNA topoisomerase I, mitochondrialtarget
DB01030TopotecanDNA topoisomerase 1target
DB01030TopotecanATP-binding cassette sub-family G member 2transporter
DB01030TopotecanMultidrug resistance protein 1transporter
DB01030TopotecanCytochrome P450 3A4enzyme
DB01030TopotecanDNAtarget
DB01033MercaptopurineThiopurine S-methyltransferaseenzyme
DB01033MercaptopurineXanthine dehydrogenase/oxidaseenzyme
DB01033MercaptopurineHypoxanthine-guanine phosphoribosyltransferasetarget
DB01033MercaptopurineSolute carrier family 22 member 8transporter
DB01033MercaptopurineMultidrug resistance-associated protein 4transporter
DB01033MercaptopurineMultidrug resistance-associated protein 5transporter
DB01033MercaptopurineSodium/nucleoside cotransporter 2transporter
DB01033MercaptopurineSolute carrier family 28 member 3transporter
DB01033MercaptopurineEquilibrative nucleoside transporter 1transporter
DB01033MercaptopurineEquilibrative nucleoside transporter 2transporter
DB01033MercaptopurineAldehyde oxidaseenzyme
DB01033MercaptopurineAmidophosphoribosyltransferasetarget
DB01033MercaptopurineInosine-5'-monophosphate dehydrogenasetarget
DB01041ThalidomideTumor necrosis factortarget
DB01041ThalidomideNuclear factor NF-kappa-B p105 subunittarget
DB01041ThalidomideProstaglandin G/H synthase 2target
DB01041ThalidomideCytochrome P450 2C19enzyme
DB01041ThalidomideCytochrome P450 1A2enzyme
DB01041ThalidomideCytochrome P450 1A1enzyme
DB01041ThalidomideCytochrome P450 2E1enzyme
DB01041ThalidomideCytochrome P450 2C9enzyme
DB01041ThalidomideProstaglandin G/H synthase 1enzyme
DB01041ThalidomideProstaglandin G/H synthase 2enzyme
DB01041ThalidomideCytochrome P450 3A5enzyme
DB01041ThalidomideFibroblast growth factor receptor 2target
DB01041ThalidomideDNAtarget
DB01041ThalidomideProtein cereblontarget
DB01041ThalidomideNuclear factor kappa-light-chain-enhancer of activated B cellstarget
DB01041Thalidomidealpha1-acid glycoproteintarget
DB01042MelphalanDNAtarget
DB01042MelphalanSolute carrier family 22 member 3transporter
DB01042MelphalanLarge neutral amino acids transporter small subunit 1transporter
DB01073FludarabineDNA polymerase alpha catalytic subunittarget
DB01073FludarabineRibonucleoside-diphosphate reductase large subunittarget
DB01073FludarabineEquilibrative nucleoside transporter 1transporter
DB01073FludarabineDNAtarget
DB01073FludarabineDeoxycytidine kinasetarget
DB01073FludarabineSolute carrier family 28 member 3transporter
DB01099FlucytosineThymidylate synthasetarget
DB01099FlucytosineDNA (cytosine-5)-methyltransferase 1target
DB01099FlucytosineDNAtarget
DB01101CapecitabineThymidylate synthasetarget
DB01101CapecitabineThymidine phosphorylaseenzyme
DB01101CapecitabineCytidine deaminaseenzyme
DB01101CapecitabineLiver carboxylesterase 1enzyme
DB01101CapecitabineDihydropyrimidine dehydrogenase [NADP(+)]enzyme
DB01101CapecitabineCytochrome P450 2C9enzyme
DB01101CapecitabineDNAtarget
DB01101CapecitabineRNAtarget
DB01168ProcarbazineDNAtarget
DB01168ProcarbazineXanthine dehydrogenase/oxidaseenzyme
DB01168ProcarbazineCytochrome P450 1B1enzyme
DB01168ProcarbazineMonoamine oxidasetarget
DB01169Arsenic trioxideInhibitor of nuclear factor kappa-B kinase subunit betatarget
DB01169Arsenic trioxideTranscription factor AP-1target
DB01169Arsenic trioxideG1/S-specific cyclin-D1target
DB01169Arsenic trioxideMitogen-activated protein kinase 3target
DB01169Arsenic trioxideMitogen-activated protein kinase 1target
DB01169Arsenic trioxideRAC-alpha serine/threonine-protein kinasetarget
DB01169Arsenic trioxideCytochrome P450 1A1enzyme
DB01169Arsenic trioxideCanalicular multispecific organic anion transporter 1transporter
DB01169Arsenic trioxideThioredoxin reductase 1, cytoplasmictarget
DB01169Arsenic trioxideMultidrug resistance protein 1transporter
DB01169Arsenic trioxideCytochrome P450 1B1enzyme
DB01169Arsenic trioxideCytochrome P450 3A4enzyme
DB01169Arsenic trioxideCyclin-dependent kinase inhibitor 1target
DB01169Arsenic trioxideHistone deacetylase 1target
DB01169Arsenic trioxideProtein PMLtarget
DB01169Arsenic trioxideSerum albumincarrier
DB01177IdarubicinDNA topoisomerase 2-alphatarget
DB01177IdarubicinDNAtarget
DB01177IdarubicinMultidrug resistance-associated protein 1transporter
DB01177IdarubicinCytochrome P450 2C9enzyme
DB01177IdarubicinCytochrome P450 2D6enzyme
DB01181IfosfamideCytochrome P450 2B6enzyme
DB01181IfosfamideDNAtarget
DB01181IfosfamideCytochrome P450 3A4enzyme
DB01181IfosfamideCytochrome P450 3A5enzyme
DB01181IfosfamideCytochrome P450 2C9enzyme
DB01181IfosfamideCytochrome P450 2C8enzyme
DB01181IfosfamideCytochrome P450 2A6enzyme
DB01181IfosfamideCytochrome P450 2C19enzyme
DB01181IfosfamideCytochrome P450 2C18enzyme
DB01181IfosfamideProstaglandin G/H synthase 1enzyme
DB01181IfosfamideCytochrome P450 3A7enzyme
DB01181IfosfamideNuclear receptor subfamily 1 group I member 2target
DB01204MitoxantroneDNA topoisomerase 2-alphatarget
DB01204MitoxantroneCytochrome P450 2E1enzyme
DB01204MitoxantroneMultidrug resistance protein 1transporter
DB01204MitoxantroneMultidrug resistance-associated protein 1transporter
DB01204MitoxantroneATP-binding cassette sub-family G member 2transporter
DB01204MitoxantroneDNAtarget
DB01204MitoxantroneCytochrome P450 1B1enzyme
DB01204MitoxantroneCytochrome P450 3A4enzyme
DB01206LomustineDNAtarget
DB01206LomustineCytochrome P450 3A4enzyme
DB01206LomustineCytochrome P450 2D6enzyme
DB01206LomustineStathmin-4target
DB01229PaclitaxelApoptosis regulator Bcl-2target
DB01229PaclitaxelTubulin beta-1 chaintarget
DB01229PaclitaxelCytochrome P450 2C8enzyme
DB01229PaclitaxelCytochrome P450 3A4enzyme
DB01229PaclitaxelCytochrome P450 3A5enzyme
DB01229PaclitaxelCytochrome P450 3A7enzyme
DB01229PaclitaxelCytochrome P450 2C9enzyme
DB01229PaclitaxelBile salt export pumptransporter
DB01229PaclitaxelMultidrug resistance protein 1transporter
DB01229PaclitaxelMultidrug resistance-associated protein 1transporter
DB01229PaclitaxelMultidrug resistance-associated protein 7transporter
DB01229PaclitaxelCytochrome P450 19A1enzyme
DB01229PaclitaxelCytochrome P450 1B1enzyme
DB01229PaclitaxelSolute carrier organic anion transporter family member 1B3transporter
DB01229PaclitaxelNuclear receptor subfamily 1 group I member 2target
DB01229PaclitaxelMicrotubule-associated protein 4target
DB01229PaclitaxelMicrotubule-associated protein 2target
DB01229PaclitaxelMicrotubule-associated protein tautarget
DB01229PaclitaxelATP-binding cassette sub-family G member 2transporter
DB01229PaclitaxelCanalicular multispecific organic anion transporter 1transporter
DB01248DocetaxelApoptosis regulator Bcl-2target
DB01248DocetaxelTubulin beta-1 chaintarget
DB01248DocetaxelCytochrome P450 3A4enzyme
DB01248DocetaxelCytochrome P450 3A5enzyme
DB01248DocetaxelCytochrome P450 3A7enzyme
DB01248DocetaxelMultidrug resistance protein 1transporter
DB01248DocetaxelMultidrug resistance-associated protein 7transporter
DB01248DocetaxelCytochrome P450 1B1enzyme
DB01248DocetaxelMicrotubule-associated protein 2target
DB01248DocetaxelMicrotubule-associated protein 4target
DB01248DocetaxelMicrotubule-associated protein tautarget
DB01248DocetaxelSolute carrier organic anion transporter family member 1B3transporter
DB01248DocetaxelSolute carrier family 22 member 7transporter
DB01248DocetaxelATP-binding cassette sub-family G member 2transporter
DB01248DocetaxelCanalicular multispecific organic anion transporter 1transporter
DB01248DocetaxelMultidrug resistance-associated protein 1transporter
DB01248DocetaxelNuclear receptor subfamily 1 group I member 2target
DB01254DasatinibTyrosine-protein kinase ABL1target
DB01254DasatinibAbelson tyrosine-protein kinase 2target
DB01254DasatinibProto-oncogene tyrosine-protein kinase Srctarget
DB01254DasatinibTyrosine-protein kinase Fyntarget
DB01254DasatinibTyrosine-protein kinase Lcktarget
DB01254DasatinibTyrosine-protein kinase Yestarget
DB01254DasatinibMast/stem cell growth factor receptor Kittarget
DB01254DasatinibPlatelet-derived growth factor receptor betatarget
DB01254DasatinibEphrin type-A receptor 2target
DB01254DasatinibSignal transducer and activator of transcription 5Btarget
DB01254DasatinibCytochrome P450 3A4enzyme
DB01254DasatinibMultidrug resistance protein 1transporter
DB01254DasatinibATP-binding cassette sub-family G member 2transporter
DB01254DasatinibCytochrome P450 1A1enzyme
DB01254DasatinibCytochrome P450 1A2enzyme
DB01254DasatinibCytochrome P450 1B1enzyme
DB01254DasatinibCytochrome P450 3A5enzyme
DB01254DasatinibDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB01254DasatinibTyrosine-protein kinase BTKtarget
DB01254DasatinibNuclear receptor subfamily 4 group A member 3target
DB01254DasatinibBreakpoint cluster region proteintarget
DB01254DasatinibTyrosine-protein kinase CSKtarget
DB01254DasatinibEphrin type-A receptor 5target
DB01254DasatinibEphrin type-B receptor 4target
DB01254DasatinibTyrosine-protein kinase Fgrtarget
DB01254DasatinibTyrosine-protein kinase FRKtarget
DB01254DasatinibHeat shock cognate 71 kDa proteintarget
DB01254DasatinibTyrosine-protein kinase Lyntarget
DB01254DasatinibMitogen-activated protein kinase kinase kinase MLTtarget
DB01254DasatinibMitogen-activated protein kinase 14target
DB01254DasatinibAmidophosphoribosyltransferasetarget
DB01262DecitabineDNAtarget
DB01262DecitabineDNA (cytosine-5)-methyltransferase 1target
DB01262DecitabineDeoxycytidine kinaseenzyme
DB01280NelarabineDNAtarget
DB01280NelarabineAdenosine deaminaseenzyme
DB01280NelarabineDeoxycytidine kinaseenzyme
DB01280NelarabineDeoxyguanosine kinase, mitochondrialenzyme
DB01280NelarabineDNA polymerase alpha catalytic subunittarget
DB01590EverolimusSerine/threonine-protein kinase mTORtarget
DB01590EverolimusCytochrome P450 3A4enzyme
DB02546VorinostatHistone deacetylase 1target
DB02546VorinostatHistone deacetylase 2target
DB02546VorinostatHistone deacetylase 3target
DB02546VorinostatHistone deacetylase 6target
DB02546VorinostatHistone deacetylase 8target
DB02546VorinostatAcetoin utilization proteintarget
DB04572ThiotepaCytochrome P450 2B6enzyme
DB04572ThiotepaCytochrome P450 3A4enzyme
DB04572ThiotepaDNAtarget
DB04845IxabepiloneTubulin beta-3 chaintarget
DB04845IxabepiloneCytochrome P450 3A4enzyme
DB04868NilotinibTyrosine-protein kinase ABL1target
DB04868NilotinibMast/stem cell growth factor receptor Kittarget
DB04868NilotinibCytochrome P450 2D6enzyme
DB04868NilotinibCytochrome P450 2C8enzyme
DB04868NilotinibCytochrome P450 2C9enzyme
DB04868NilotinibCytochrome P450 3A4enzyme
DB04868NilotinibMultidrug resistance protein 1transporter
DB04868NilotinibATP-binding cassette sub-family G member 2transporter
DB04868NilotinibUDP-glucuronosyltransferase 1-1transporter
DB04868NilotinibCytochrome P450 2B6enzyme
DB05015BelinostatHistone deacetylasetarget
DB05015BelinostatCytochrome P450 1A2enzyme
DB05015BelinostatUDP-glucuronosyltransferase 1A1enzyme
DB05015BelinostatCytochrome P450 2C8enzyme
DB05015BelinostatCytochrome P450 2C9enzyme
DB05015BelinostatMultidrug resistance protein 1transporter
DB05109TrabectedinCytochrome P450 3A4enzyme
DB05109TrabectedinCytochrome P450 2C9enzyme
DB05109TrabectedinCytochrome P450 2D6enzyme
DB05109TrabectedinCytochrome P450 2E1enzyme
DB05109TrabectedinCytochrome P450 2C19enzyme
DB05109TrabectedinDNAtarget
DB05109TrabectedinProstaglandin G/H synthase 1enzyme
DB05773Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
DB05773Trastuzumab emtansineMultidrug resistance protein 1transporter
DB05773Trastuzumab emtansineCytochrome P450 3A4enzyme
DB05773Trastuzumab emtansineCytochrome P450 3A5enzyme
DB06287TemsirolimusSerine/threonine-protein kinase mTORtarget
DB06287TemsirolimusCytochrome P450 3A4enzyme
DB06287TemsirolimusCytochrome P450 3A5enzyme
DB06287TemsirolimusCytochrome P450 3A7enzyme
DB06287TemsirolimusCytochrome P450 2D6enzyme
DB06287TemsirolimusMultidrug resistance protein 1transporter
DB06616BosutinibBreakpoint cluster region proteintarget
DB06616BosutinibTyrosine-protein kinase ABL1target
DB06616BosutinibTyrosine-protein kinase Lyntarget
DB06616BosutinibTyrosine-protein kinase HCKtarget
DB06616BosutinibProto-oncogene tyrosine-protein kinase Srctarget
DB06616BosutinibMultidrug resistance protein 1transporter
DB06616BosutinibCytochrome P450 3A4enzyme
DB06616BosutinibCyclin-dependent kinase 2target
DB06616BosutinibDual specificity mitogen-activated protein kinase kinase 1target
DB06616BosutinibDual specificity mitogen-activated protein kinase kinase 2target
DB06616BosutinibMitogen-activated protein kinase kinase kinase 2target
DB06616BosutinibCalcium/calmodulin-dependent protein kinase type II subunit gammatarget
DB06769BendamustineCytochrome P450 1A2enzyme
DB06772CabazitaxelCytochrome P450 3A4enzyme
DB06772CabazitaxelCytochrome P450 3A5enzyme
DB06772CabazitaxelCytochrome P450 2C8enzyme
DB06772CabazitaxelMultidrug resistance protein 1transporter
DB06772CabazitaxelATP-binding cassette sub-family G member 2transporter
DB06772CabazitaxelTubulin alpha-4A chaintarget
DB06772CabazitaxelTubulin beta-1 chaintarget
DB06772CabazitaxelSolute carrier organic anion transporter family member 1B1transporter
DB06772CabazitaxelSolute carrier organic anion transporter family member 1B3transporter
DB08871EribulinApoptosis regulator Bcl-2target
DB08871EribulinTubulin beta-1 chaintarget
DB08877RuxolitinibTyrosine-protein kinase JAK1target
DB08877RuxolitinibTyrosine-protein kinase JAK2target
DB08877RuxolitinibCytochrome P450 3A4enzyme
DB08889CarfilzomibMultidrug resistance protein 1transporter
DB08889CarfilzomibProteasome subunit beta type-5target
DB08889CarfilzomibProteasome subunit beta type-9target
DB08889CarfilzomibProteasome subunit beta type-10target
DB08889CarfilzomibProteasome subunit beta type-8target
DB08889CarfilzomibProteasome subunit beta type-1target
DB08889CarfilzomibProteasome subunit beta type-2target
DB08895TofacitinibNon-receptor tyrosine-protein kinase TYK2target
DB08895TofacitinibCytochrome P450 3A4enzyme
DB08895TofacitinibCytochrome P450 2C19enzyme
DB08895TofacitinibTyrosine-protein kinase JAK2target
DB08895TofacitinibTyrosine-protein kinase JAK1target
DB08895TofacitinibTyrosine-protein kinase JAK3target
DB08895TofacitinibSerum albumincarrier
DB08901PonatinibTyrosine-protein kinase ABL1target
DB08901PonatinibBreakpoint cluster region proteintarget
DB08901PonatinibMast/stem cell growth factor receptor Kittarget
DB08901PonatinibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB08901PonatinibAngiopoietin-1 receptortarget
DB08901PonatinibReceptor-type tyrosine-protein kinase FLT3target
DB08901PonatinibCytochrome P450 3A4enzyme
DB08901PonatinibCytochrome P450 2C8enzyme
DB08901PonatinibCytochrome P450 2D6enzyme
DB08901PonatinibCytochrome P450 3A5enzyme
DB08901PonatinibMultidrug resistance protein 1transporter
DB08901PonatinibATP-binding cassette sub-family G member 2transporter
DB08901PonatinibFibroblast growth factor receptor 1target
DB08901PonatinibFibroblast growth factor receptor 2target
DB08901PonatinibFibroblast growth factor receptor 3target
DB08901PonatinibFibroblast growth factor receptor 4target
DB08901PonatinibTyrosine-protein kinase Lcktarget
DB08901PonatinibProto-oncogene tyrosine-protein kinase Srctarget
DB08901PonatinibTyrosine-protein kinase Lyntarget
DB08901PonatinibVascular endothelial growth factor receptor 2target
DB08901PonatinibPlatelet-derived growth factor receptor alphatarget
DB08901PonatinibBile salt export pumptransporter
DB08910PomalidomideCytochrome P450 1A2enzyme
DB08910PomalidomideCytochrome P450 3A4enzyme
DB08910PomalidomideMultidrug resistance protein 1transporter
DB08910PomalidomideProtein cereblontarget
DB08910PomalidomideTumor necrosis factortarget
DB08910PomalidomideProstaglandin G/H synthase 2target
DB08935ObinutuzumabB-lymphocyte antigen CD20target
DB09052BlinatumomabB-lymphocyte antigen CD19target
DB09052BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
DB09053IbrutinibTyrosine-protein kinase BTKtarget
DB09053IbrutinibCytochrome P450 3A4enzyme
DB09053IbrutinibCytochrome P450 3A5enzyme
DB09053IbrutinibCytochrome P450 2D6enzyme
DB09073PalbociclibCyclin-dependent kinase 4target
DB09073PalbociclibCyclin-dependent kinase 6target
DB09073PalbociclibCytochrome P450 3A4enzyme
DB09073PalbociclibSulfotransferase 2A1enzyme
DB09074OlaparibPoly [ADP-ribose] polymerase 1target
DB09074OlaparibCytochrome P450 3A4enzyme
DB09074OlaparibCytochrome P450 2B6enzyme
DB09074OlaparibPoly [ADP-ribose] polymerase 2target
DB09074OlaparibPoly [ADP-ribose] polymerase 3target
DB09077DinutuximabGanglioside GD2target